Outpace Bio, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. (NCT07664735) | Outpace Bio, Inc. | 2026-06-30 |
| A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (NCT07030907) | Outpace Bio, Inc. | 2025-06-16 |
Track Outpace Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.